Patients and Methods

Data source and patients
This study used the Tumor Registry Database at The University of Alabama at Birmingham (UAB). Data were inquired for all patients with differentiated thyroid cancer, papillary thyroid cancer (PTC), and follicular thyroid cancer (FTC), from 1975 to 2016 who underwent any type of thyroid surgery at the UAB and/or were referred for further management after their thyroid surgery. The UAB Institutional Review Board for Human Use committee approved this retrospective study. Those patients with histological type other than PTC or FTC or with metastatic disease on presentation were excluded from the analysis. This database contains information about patients' demographics including age, sex, race, tumor clinical and pathological stages, and mortality.
Outcomes measurement
We divided the cohort into 4 groups: white males, white females, nonwhite males, and nonwhite females. The overall 10-and 20-year survival rates were evaluated among these groups. Patients' survival rate was obtained from the Tumor Registry Database and calculated from the date of diagnosis. Based on the result of the nonadjusted model, mortality risk of the group with the worst overall 10-and 20-year survival rate, nonwhite males, was compared with the rest of the cohort, white males, white females (reference group), and nonwhite females. Factors included in the adjusted model are age, cancer type, stage (AJCC 7th Ed Cancer Staging Manual, 2010), surgical procedure, radioactive iodine (RAI), and year of surgery.
Statistical analysis
Continuous variables are summarized as mean ± SD and t tests were used to evaluate association for outcome. Chi-square was used for categorical variables. Age was divided to 2 groups, younger than 45 (⩽45) and older than 45 (>45) to be in line with clinical staging criteria for thyroid cancer before the new American Thyroid Association (ATA) 2015 guidelines. Cox proportional hazard models were used for multivariable analyses. We did not conduct any univariate analysis and variables included in the multivariable analysis were those that have been shown to affect survival among patients with differentiated thyroid cancer. We used the Kaplan-Meier method and log rank tests to compare unadjusted overall survival between different racial/gender groups and parametric hazard analysis to identify risk factors for mortality. Of note, because race is a fixed parameter, and the testing of time-varying parameters' interactions was insignificant, we did not test for time interaction in our method. P value with significance level set at P < .05, adjusted hazard ratio (HR), and 95% confidence interval (CI) are reported. Data management and analysis were performed using SAS software, Version 9.4. (SAS Institute Inc., Cary, NC, USA).
Results
Patient demographics and clinical characteristics
Over the past 45 years, a total of 1584 patients with well differentiated thyroid cancer were identified. Of those, there were 1440 (91%) patients with papillary cancer and 144 (9%) patients with follicular thyroid cancer. A total of 1131 (71%) patients were woman and 909 (57%) were older than 45 years with no significant difference in age/sex among groups. Race/ethnicity included 805 (51%) white, 161 (10%) African Americans, and 618 (39%) other groups. Thyroid surgery was divided between total thyroidectomy (n = 1297 patients [82%]), lobectomy (n = 261 patients [16.5%]), and other surgical procedures (n = 26 [1.5%]). A total of 767 (48%) received RAI. The patients' characteristics are displayed in Table 1 . A total of 313 patients (20%) had a stage III or greater disease, and lymph nodes were positive in 340 patients (22%) ( Table 1) . Table 2 
demonstrates the
Outcomes analyses
When analyzed by race and gender, the 10-and 20-year survival in nonwhite males of 81.8% and 63.5%, respectively, was significantly lower than that of nonwhite females (90.5% and 66.0%), white males (92.4% and 82.3%), and white females (95.8% and 90.8%; P < .0001; Figure 1 ). The median survival for nonwhite males, nonwhite females, white males, and white females is 6.7, 6.8, 4.6, and 5.2 years, respectively. The median follow-up for the total cohort was 5.9 years. We used univariate analysis to identify variables that have an effect on survival. After controlling for age, cancer type, stage, surgical procedure, RAI, and year of surgery, nonwhite males had a higher mortality risk with HR of 1.58 compared with nonwhite females (P = .0376, CI: 1.03-2.43), HR of 3.50 compared with white males (P < .0001, CI: 1.88-6.54), and HR of 4.78 compared with white females (P < .0001, CI: 3.31-9.9) ( Table 3 ). In a univariate cox regression model, only age ⩾55 was associated with statistically significant increased HR of worse outcome (HR: 2.84, 95% CI: 1.13-7.12, P = .03; Table 4 ). 
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Discussion
Using a large tumor registry database from 1975 to 2016 at a busy tertiary referral center that provides care for diverse gender and racial groups, this study demonstrates a gender and racial disparity in survival after surgery among patients with papillary and follicular thyroid cancer. Our results show that nonwhite males have worse 10-and 20-year survival rates when compared with white males, white females, and nonwhite female with a higher mortality risk compared with these groups.
Although not investigated in our study, several factors such as genetic and molecular differences between races and genders, disease presentation and socioeconomic factors likely play an important role in the observed disparities in survival among minorities with thyroid cancer. 12 A meta-analysis showed a difference in BRAF status by race/ethnicity and gender. As BRAF mutations are associated with aggressive tumor and disease behaviors, and therefore worse outcome, however, the contribution of this mutation to outcomes in our study cannot be measured. 16 Advanced presentation and tumors with aggressive features such as extrathyroidal extension, with corresponding worse prognosis, have been found more prevalent among patients with ethnic minorities. 17 In one study of 25 945 patients with differentiated thyroid cancer that used the California Cancer Registry, minority groups were found to have a higher percentage of metastatic and regional disease at presentation, as compared with white patients. 14 These findings are in alignment with our results in which we showed that nonwhite males are more likely to present with more positive lymph node metastasis, advance clinical stage and less likely to receive RAI or undergo total thyroidectomy compared with white females. Consistent with our findings, this study found lower overall and adjusted survival rates among black patients. Similarly, Moo-Young et al 15 found that African Americans aged <45 years are less likely to have lymph node involvement but had the largest tumor size in presentation. Furthermore, in this study, advanced stage IV disease was found to be more prevalent among Asian Americans. Asban et al 5 Socioeconomic status has also been shown to play a vital role in disparities in presentation and outcomes among patients with thyroid cancer. In one study, only 2% of patients had insurance at the public hospital where 96% of patients were ethnic minorities, compared with 85% with insurance at the university hospital. 18 Furthermore, investigating the sociodemographic disparities in differentiated thyroid cancer survival among adolescents and young adults, Keegan et al have found that African American or Hispanic race/ethnicity (vs non-Hispanic whites) had worse thyroid cancer-specific survival. This study showed worse thyroid cancer-specific survival among adolescent and young adult men from low socioeconomic status neighborhoods and nonmetropolitan areas; however, these findings did not hold true among women.
In addition, in the SEER database, African American patients had worse overall and adjusted survival vs nonblack patients among 17 668 patients diagnosed with papillary thyroid microcarcinoma between 1988 and 2009, 19 which is consistent with our findings.
This study has several limitations. First, we were not able to adjust for some clinical and tumor pathological features that may affect patients' survival, such as extrathyroidal tumor extension, capsular invasion, and angioinvasion. Second, the Tumor Registry Database is missing information on patients' socioeconomic status, such as annual income, level of education, insurance type, and marital status, whcich have a direct effect on disparities among different races. Third, we could not obtain disease-specific survival to accurately estimate thyroid cancer-related survival. Still, our overall survival rate was consistent with previous publications.
Conclusions
Our diverse cohort demonstrates significant gender and racial disparities in survival after thyroid cancer surgery. To improve health outcomes and reduce disparities among nonwhite males, interventions and long-term care management should target potentially modifiable causes of worse outcomes in this group, and future research should be directed to further understand why disparities exist among minorities.
